CY1109140T1 - Τυποποιησεις εμβολιων που περιλαμβανουν αντιιδιοτυπικα αντισωματα τα οποια μιμουνται ανοσολογικα υαδατανθρακες των στρεπτοκοκκων ομαδας β - Google Patents

Τυποποιησεις εμβολιων που περιλαμβανουν αντιιδιοτυπικα αντισωματα τα οποια μιμουνται ανοσολογικα υαδατανθρακες των στρεπτοκοκκων ομαδας β

Info

Publication number
CY1109140T1
CY1109140T1 CY20091100604T CY091100604T CY1109140T1 CY 1109140 T1 CY1109140 T1 CY 1109140T1 CY 20091100604 T CY20091100604 T CY 20091100604T CY 091100604 T CY091100604 T CY 091100604T CY 1109140 T1 CY1109140 T1 CY 1109140T1
Authority
CY
Cyprus
Prior art keywords
outcomes
immunological
carbons
street
immune
Prior art date
Application number
CY20091100604T
Other languages
Greek (el)
English (en)
Inventor
Giuseppe Teti
Luciano Polonelli
Original Assignee
Novartis Vaccines And Diagnostics S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines And Diagnostics S.R.L. filed Critical Novartis Vaccines And Diagnostics S.R.L.
Publication of CY1109140T1 publication Critical patent/CY1109140T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4233—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-bacterial Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CY20091100604T 1998-04-20 2009-06-09 Τυποποιησεις εμβολιων που περιλαμβανουν αντιιδιοτυπικα αντισωματα τα οποια μιμουνται ανοσολογικα υαδατανθρακες των στρεπτοκοκκων ομαδας β CY1109140T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9808327.2A GB9808327D0 (en) 1998-04-20 1998-04-20 Antidiotypic compounds
EP99914725A EP1071763B1 (en) 1998-04-20 1999-04-20 Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group b streptococcal carbohydrates

Publications (1)

Publication Number Publication Date
CY1109140T1 true CY1109140T1 (el) 2014-07-02

Family

ID=10830608

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100604T CY1109140T1 (el) 1998-04-20 2009-06-09 Τυποποιησεις εμβολιων που περιλαμβανουν αντιιδιοτυπικα αντισωματα τα οποια μιμουνται ανοσολογικα υαδατανθρακες των στρεπτοκοκκων ομαδας β

Country Status (9)

Country Link
US (2) US6676938B1 (https=)
EP (1) EP1071763B1 (https=)
JP (2) JP4446601B2 (https=)
AT (1) ATE425251T1 (https=)
CA (1) CA2325566C (https=)
CY (1) CY1109140T1 (https=)
DE (1) DE69940545D1 (https=)
GB (1) GB9808327D0 (https=)
WO (1) WO1999054457A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1181058A2 (de) * 1999-05-27 2002-02-27 Max-Delbrück-Centrum Für Molekulare Medizin Vakzine gegen konformationsabhängige antigene sowie gegen antigene, die keine oder nicht ausschliesslich proteine oder peptide sind
CA2881568C (en) 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups a & b
US20070053924A1 (en) * 2002-08-26 2007-03-08 Herve Tettelin Conserved and specific streptococcal genomes
ES2505695T3 (es) 2003-07-31 2014-10-10 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunógenas para Streptococcus pyogenes
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
JP2008508320A (ja) 2004-07-29 2008-03-21 カイロン コーポレイション Ｓｔｒｅｐｔｏｃｏｃｃｕｓａｇａｌａｃｔｉａｅのようなグラム陽性細菌に対する免疫原性組成物
US7838010B2 (en) * 2004-10-08 2010-11-23 Novartis Vaccines And Diagnostics S.R.L. Immunogenic and therapeutic compositions for Streptococcus pyogenes
JP2008525033A (ja) * 2004-12-22 2008-07-17 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Ｂ群連鎖球菌
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
PT2054431E (pt) * 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
CA2668018A1 (en) * 2006-10-30 2008-09-12 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
KR101621837B1 (ko) 2007-09-12 2016-05-17 노파르티스 아게 Ｇａｓ57 돌연변이 항원 및 ｇａｓ57 항체
EP2537857B1 (en) 2007-12-21 2017-01-18 GlaxoSmithKline Biologicals SA Mutant forms of streptolysin O
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
EP3773348B1 (en) 2018-04-10 2025-04-02 Alps Holding Llc Spinal interbody cage comprising top and bottom faces with mesh structures, pillars and slots

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476784A (en) * 1993-04-06 1995-12-19 Rice; Peter A. Gonococcal anti-idiotypic antibodies and methods and compositions using them
JP2000512490A (ja) * 1996-05-29 2000-09-26 デレク ナイジェル ジョン ハート 樹状細胞のレセプター
US6140091A (en) * 1997-06-20 2000-10-31 Boston Biomedical Research Institute Anti-idiotype vaccines to elicit catalytic antibodies
CA2317029A1 (en) * 1997-12-31 1999-07-08 Seth H. Pincus A method of isolating a peptide which immunologically mimics microbial carbohydrates including group b streptococcal carbohydrates and the use thereof in a vaccine

Also Published As

Publication number Publication date
US6900302B2 (en) 2005-05-31
EP1071763B1 (en) 2009-03-11
JP2009179645A (ja) 2009-08-13
CA2325566C (en) 2011-02-08
JP4446601B2 (ja) 2010-04-07
US20040101536A1 (en) 2004-05-27
JP2002512026A (ja) 2002-04-23
CA2325566A1 (en) 1999-10-28
DE69940545D1 (de) 2009-04-23
GB9808327D0 (en) 1998-06-17
EP1071763A1 (en) 2001-01-31
ATE425251T1 (de) 2009-03-15
US6676938B1 (en) 2004-01-13
WO1999054457A1 (en) 1999-10-28

Similar Documents

Publication Publication Date Title
CY1109140T1 (el) Τυποποιησεις εμβολιων που περιλαμβανουν αντιιδιοτυπικα αντισωματα τα οποια μιμουνται ανοσολογικα υαδατανθρακες των στρεπτοκοκκων ομαδας β
CY1119650T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
DK1093381T4 (da) Antigene peptider afledt fra teleromerase
WO2005058937A3 (en) A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1
CY1108083T1 (el) Αντιγονα και συνθεσεις του neisseria meningitidis
DK1584685T3 (da) Tumorassocieret antigenderivater fra Mage-familien, anvendt til fremstilling af fusionsproteiner med T-hjælper epitoper og sammensætninger til vaccination
DK53687A (da) Peptid_fra htlv-iii-viruskappeprotein
ATE542829T1 (de) Impfstoff
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
CY1115842T1 (el) Συμπληρωμενο ομv εμβολιο κατα μηνιγγιtiδοκοκκου
CY1114722T1 (el) Αντιγονα στρεπτοκοκκου
CY1116506T1 (el) Αντισωματα εναντι masp-2
CY1106532T1 (el) Ετερολογος εκφραση των πρωτεϊνων της neisseria
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
CY1114333T1 (el) Αντιγονα του neisseria meningitidis
CO5050400A1 (es) Proteina de chlamydia, secuencia de genes y anticuerpos para ello
NO991524L (no) Vaksiner
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
DE69111801D1 (de) Vakzin gegen hepatitis b.
EP1242049A4 (en) VACCINE COMPOSITIONS AND ANTIGEN PEPTIDES ASSOCIATED WITH CLASS I HLA-A2 TUMOR
NO20004413D0 (no) HIV peptider, antigener, vaksine, blandinger, immunoassay, kit og en fremgangmÕte for pÕvisning av antistoffer som blir infusert av HIV
CY1111286T1 (el) Ανοσοποιηση διαμεσολαβουμενη απο βακτηριοφαγα
ATE370745T1 (de) Verbesserte polysaccharid- und glykokonjugat- vakzine
CY1107322T1 (el) Συνδυασμενο εμβολιο κατα της hπατιτιδας α και ηπατιτιδας β
DE69922212D1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)